Rxivist logo

Rxivist combines preprints from bioRxiv with data from Twitter to help you find the papers being discussed in your field. Currently indexing 62,719 bioRxiv papers from 278,291 authors.

The proton pump inhibitor omeprazole does not promote Clostridium difficile colonization in a murine model

By Sarah T Tomkovich, Nicholas A Lesniak, Yuan Li, Lucas Bishop, Madison J Fitzgerald, Patrick D Schloss

Posted 19 Sep 2019
bioRxiv DOI: 10.1101/775411

Proton pump inhibitor (PPI) use has been associated with microbiota alterations and susceptibility to Clostridium difficile infections (CDIs) in humans. We assessed how PPI treatment alters the fecal microbiota and whether treatment promotes CDIs in a mouse model. Mice receiving a PPI treatment were gavaged with 40 mg/kg of omeprazole during a 7-day pretreatment phase, the day of C. difficile challenge, and the following 9 days. We found that mice treated with omeprazole were not colonized by C. difficile. When omeprazole treatment was combined with a single clindamycin treatment, one cage of mice remained resistant to C. difficile colonization, while the other cage was colonized. Treating mice with only clindamycin followed by challenge resulted in C. difficile colonization. 16S rRNA gene sequencing analysis revealed that omeprazole had minimal impact on the structure of the murine microbiota throughout the 16 days of omeprazole exposure. These results suggest omeprazole treatment alone is not sufficient to disrupt microbiota resistance to C. difficile infection in mice that are normally resistant in the absence of antibiotic treatment.

Download data

  • Downloaded 44 times
  • Download rankings, all-time:
    • Site-wide: 60,875 out of 62,719
    • In microbiology: 4,860 out of 5,020
  • Year to date:
    • Site-wide: 59,455 out of 62,719
  • Since beginning of last month:
    • Site-wide: 10,023 out of 62,719

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide

Sign up for the Rxivist weekly newsletter! (Click here for more details.)